LeMaitre Vascular Q3 sales slightly beat estimates on EMEA performance

What happened

LeMaitre Vascular said third-quarter sales rose 11% and slightly beat analyst expectations, supported by graft and shunt sales and stronger EMEA performance. It had acquired B. Braun vascular assets, expanding its product portfolio outside North America, and issued fourth-quarter and full-year 2026 forecasts.

Confirmed

Global impact / market context

Higher selling prices and more units sold both contributed to organic growth, while the acquired B. Braun vascular assets broadened LeMaitre’s products beyond North America. If these drivers continue, they could support revenue growth; however, the article does not establish how much the acquisition contributed to sales or costs.

Analyst inference

Sales growth can support revenue and earnings if higher prices and unit sales persist, while broad regional gains may reduce dependence on one market. The article also reports the company’s current average analyst rating as buy, but gives no share-price response or evidence of changed investor expectations.

Analyst inference

What to watch

1. Compare reported fourth-quarter sales with the company’s forecast range to assess whether growth continues; sales below that outlook could weaken revenue expectations. Analyst inference
2. Check whether graft and shunt sales continue to grow, because these product lines drove third-quarter gains and could materially shape future revenue. Analyst inference
3. Look for updates on the acquired B. Braun vascular assets and whether their expanded product range outside North America contributes to sales or brings additional costs. Analyst inference

Evidence

• Original source link unavailable